Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jun;43(6):1406-11.
doi: 10.1128/AAC.43.6.1406.

In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model

M Wolff  1 , M L Joly-Guillou, R Farinotti, C Carbon
Affiliations

In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model

M Wolff et al. Antimicrob Agents Chemother. 1999 Jun.

Abstract

The effects of various regimens containing combinations of beta-lactams, beta-lactam inhibitor(s), and rifampin were assessed in a recently described mouse model of Acinetobacter baumannii pneumonia (M. L. Joly-Guillou, M. Wolff, J. J. Pocidalo, F. Walker, and C. Carbon, Antimicrob. Agents Chemother. 41:345-351, 1997). Two aspects of the therapeutic response were studied: the kinetics of the bactericidal effect (treatment was initiated 3 h after intratracheal inoculation, and bacterial counts were determined over a 24-h period) and survival (treatment was initiated 8 h after inoculation, and the cumulative mortality rate was assessed on day 5). Two clinical strains were used: a cephalosporinase-producing strain (SAN-94040) and a multiresistant strain (RCH-69). For SAN-94040 and RCH-69, MICs and MBCs (milligrams per liter) were as follows: ticarcillin, 32, 64, 256, and >256, respectively; ticarcillin-clavulanate, 32, 64, and 512, and >512, respectively; imipenem, 0.5, 0.5, 8, and 32, respectively; sulbactam, 0.5, 0.5, 8, and 8, respectively; and rifampin, 8, 8, 4, and 4, respectively. Against SAN-94040, four regimens, i.e., imipenem, sulbactam, imipenem-rifampin, and ticarcillin-clavulanate (at a 25/1 ratio)-sulbactam produced a true bactericidal effect (>/=3-log10 reduction of CFU/g of lung). The best survival rate (i.e., 93%) was obtained with the combination of ticarcillin-clavulanate-sulbactam, and regimens containing rifampin provided a survival rate of >/=65%. Against RCH-69, only regimens containing rifampin and the combination of imipenem-sulbactam had a true bactericidal effect. The best survival rates (>/=80%) were obtained with regimens containing rifampin and sulbactam. These results suggest that nonclassical combinations of beta-lactams, beta-lactamase inhibitors, and rifampin should be considered for the treatment of nosocomial pneumonia due to A. baumannii.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Cumulative survival rates of treated and control mice challenged with 108 CFU of A. baumannii SAN-94040 (a and b) or RCH-69 (c and d) per mouse. The treatment was initiated 8 h after intratracheal bacterial inoculation (five i.p. doses of β-lactams and one i.p. dose of rifampin). Symbols for monotherapy (a and c): ●, controls; ○, imipenem; □, sulbactam; ▵, ticarcillin; ▴, ticarcillin-clavulanate; ■, rifampin. Symbols for combinations (b and d): ○, rifampin-imipenem; □, rifampin-sulbactam; ▴, imipenem-sulbactam; ▵, ticarcillin-sulbactam; ▴, ticarcillin-clavulanate (25/1 ratio)-sulbactam; ■, rifampin-ticarcillin-clavulanate (25/1 ratio)-sulbactam. The number of mice in each group is indicated in parentheses.
See this image and copyright information in PMC

References

    1. Anstey N M, Curry B J, Withnall K M. Community-acquired Acinetobacter pneumonia in the northern territory of Australia. Clin Infect Dis. 1992;14:83–91. - PubMed
    1. Boon R J, Beale A, Sutherland R. Bactericidal effects of ticarcillin-clavulanic acid against β-lactamase-producing bacteria in vivo. Antimicrob Agents Chemother. 1986;29:838–844. - PMC - PubMed
    1. Chang-Xiao L, Jia-Rong W, Yi-Li L. Pharmacokinetics of sulbactam and ampicillin in mice and in dogs. Eur J Pharmacol. 1990;183:1859–1860.
    1. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubeau F, Sora M, Pujol M, Gudiol F. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother. 1998;42:793–802. - PubMed
    1. Costa S F, Wodcock J, Child J, Caiaffa H H, Gill M, Wise R, Levin A S. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1996. Characterization of the β-lactamase and outer-membrane proteins of imipenem-resistant Acinetobacter baumannii clinical isolates from Brazil, abstr. C123; p. 56.

Publication types

MeSH terms